A high dose of psilocybin is generally defined as 25 mg of pure psilocybin, which is roughly equivalent to 2.5 grams of dried Psilocybe cubensis mushrooms. That’s the threshold used in most major clinical trials and the dose most researchers consider the start of a full psychedelic experience. Above that, 35 mg (about 3.5 grams dried) is considered a high therapeutic dose, and anything in the 50 to 60 mg range (5 to 6 grams dried) enters what researchers call a “supra-therapeutic” dose, sometimes referred to informally as a “heroic dose.”
Those numbers come with a critical caveat: they assume roughly 1% psilocybin content per gram of dried mushroom, but actual potency varies enormously. Understanding what a high dose really means requires looking at both the milligram figures and the real-world factors that make those figures unreliable outside a lab.
Clinical Trial Dosing Standards
The most widely cited psilocybin research, including landmark studies on depression and end-of-life anxiety, has used body weight-adjusted dosing. The standard formula is milligrams per 70 kilograms of body weight. In the Johns Hopkins cancer anxiety trial, for example, the high dose was 22 or 30 mg per 70 kg. Forty-nine of the 50 participants who completed the high-dose arm received 22 mg/70 kg, while the comparison “placebo-like” dose was just 1 to 3 mg/70 kg.
Interestingly, body weight may not matter as much as researchers initially assumed. A pooled analysis of 288 participants across ten Johns Hopkins studies found no significant relationship between a person’s weight and the intensity of their subjective experience, even across a wide range of body weights from 49 to 113 kg. This has led some researchers to consider fixed doses (like a flat 25 mg for everyone) rather than weight-adjusted ones. The most recent large trials, including a 2024 Nature study, used a flat 25 mg dose.
Why Mushroom Potency Is Unpredictable
The gram-to-milligram conversions that circulate online (2.5 grams equals a “standard” dose, 3.5 grams is “high”) assume a psilocybin concentration of about 1% by dry weight in Psilocybe cubensis. In reality, the variation is staggering. Laboratory analyses of P. cubensis have measured psilocybin content ranging from 0.02% to nearly 2% by dry weight. That means one batch of 2.5 grams could contain as little as 0.5 mg of psilocybin, while another batch of the same weight could contain close to 50 mg.
This variation exists not just between different species or strains but within the same strain grown under different conditions. Factors like growing substrate, harvest timing, and storage all affect potency. Two mushrooms from the same flush can differ meaningfully. Species other than cubensis widen the range even further. Psilocybe azurescens, for instance, is known to be significantly more potent per gram than cubensis, meaning the same weight in grams could produce a dramatically different experience.
This is why clinical researchers use synthetic or precisely extracted psilocybin measured to the milligram, not raw mushrooms. Any gram-based dosing guide for whole mushrooms is, at best, a rough approximation.
What a High Dose Feels Like
At 25 mg and above, psilocybin reliably produces what researchers classify as a “mystical-type experience.” The hallmark is ego dissolution: a sense that the boundaries of your self are dissolving, that you are merging with everything around you, or that “all is one.” People describe feeling profound connections to other people, to nature, or to something they interpret as a deeper reality. Some experience what feels like contact with a sacred or divine presence, regardless of whether they held religious beliefs beforehand.
Participants in clinical trials have described encountering “a great plane of consciousness” and feeling they could “reach out to anybody and connect with them.” Others report the realization that “life and death are part of one circle.” These experiences are often described as ineffable, meaning the person struggles to convey what happened in words. Pre-session briefings at research centers explicitly warn participants: “You may feel a sense that you have lost yourself, that everything is somehow connected.” Many people rate a high-dose psilocybin session among the most meaningful experiences of their lives.
The experience is not uniformly positive, though. High doses also produce challenging psychological territory: intense anxiety, confusion, fear, and a feeling of losing control. The same ego dissolution that some people find liberating can feel terrifying when it arrives uninvited or in an unsupportive environment.
Timeline of Effects
The timeline is surprisingly consistent across dose levels. Effects typically begin about 40 to 45 minutes after oral ingestion, with a range of roughly 6 minutes to 1.5 hours depending on the person and whether they’ve eaten recently. Peak intensity hits around the 2-hour mark for all doses studied (15, 25, and 30 mg).
What changes with dose is intensity and duration. At 25 mg, the average total duration of subjective effects is about 5.5 hours. At 30 mg, it stretches to roughly 6.4 hours. Peak intensity also scales with dose: participants rated the maximum strength of their experience at 73% of the strongest possible drug effect at 25 mg and 80% at 30 mg. The comedown is gradual, not abrupt, and most people feel essentially back to baseline within 6 to 7 hours.
What Happens in the Brain
A 2024 study tracking brain activity before, during, and after a 25 mg dose found that psilocybin massively disrupts the brain’s normal communication patterns. It caused more than three times the change in brain connectivity compared to a stimulant control. The core mechanism is desynchronization: brain regions that normally fire in coordinated patterns become uncoupled, and the usual distinctions between different brain networks dissolve.
The largest disruption occurs in the default mode network, a set of brain regions linked to your sense of self, your sense of time, and your ability to locate yourself in space. This is the neural correlate of ego dissolution. The network that maintains your ordinary sense of “I” essentially goes offline. Notably, the connection between the memory-processing hippocampus and the default mode network showed a persistent decrease that lasted for weeks after a single dose. This lasting change in connectivity may be part of why therapeutic benefits often outlast the acute experience by months.
Physical and Psychological Risks
Psilocybin has low physical toxicity. The lethal dose in humans is unknown, and the few documented deaths associated with psilocybin mushrooms have involved mixed drug intoxication, accidents during hallucinations, or suicide, not direct poisoning. The threshold where physical symptoms begin (nausea, muscle weakness, visual changes) is around 0.04 to 0.06 mg per kilogram of body weight, which is well below a high dose, meaning virtually everyone taking a full dose will feel something physically.
A meta-analysis of clinical trial data found that the most common adverse effects at therapeutic doses are nausea (4% to 48% of participants, higher at higher doses), headache (2% to 66%), elevated blood pressure, anxiety, and dizziness. The blood pressure effect is notable: in one trial, 76% of participants experienced elevated blood pressure at a therapeutic dose, and in another, 34% had systolic readings above 160 mmHg on a high dose. Heart rate increases were modest, peaking in the 70s to 80s beats per minute.
Serious psychological adverse events are rare in supervised settings. Across 128 patients receiving high-dose psilocybin in clinical trials, only 3 cases of paranoia were reported. Transient thought disorder occurred in 5 out of 103 patients across two studies. Psilocybin was not statistically associated with increased risk of paranoia or thought disorder compared to placebo. Persistent visual disturbances and prolonged psychological distress remain possibilities that warrant long-term monitoring, but they appear uncommon in controlled environments with proper screening and support.
Why “High Dose” Depends on Context
The gap between a clinical high dose and what someone might experience with whole mushrooms is significant. In a research setting, 25 mg of synthetic psilocybin is delivered in a precise capsule to a screened participant who has been prepared over multiple sessions, lies on a couch with eyeshades and headphones, and has two trained guides present for the entire 6-hour experience. The same milligram quantity consumed as whole mushrooms in an uncontrolled setting, with unknown potency and no psychological support, represents a fundamentally different risk profile.
The numbers are a starting point, not a guarantee. Individual sensitivity varies, potency of natural mushrooms is inherently inconsistent, and set and setting shape the experience as powerfully as the dose itself. What’s “high” for one person at 25 mg may be moderate for another, and a 2.5-gram mushroom dose could contain anywhere from a fraction of a clinical dose to double it.